### BONE-B (2 of 5)

**Internal request:**

Comment to consider the inclusion of vincristine to the regimen irinotecan ± temozolomide for second-line relapsed/refractory or metastatic Ewing sarcoma.

**Panel Discussion/References**

*Addition at call/meeting*

Based on the data in the noted references and discussion, the panel consensus was to include vincristine to the regimen irinotecan ± temozolomide as an option for second-line relapsed/refractory or metastatic Ewing sarcoma. This is a category 2A recommendation.


**Removal at call/meeting**

Based on the data in the noted reference and discussion, the panel consensus was to remove the regimen vincristine + irinotecan in favor of irinotecan ± temozolomide ± vincristine for second-line relapsed/refractory or metastatic Ewing sarcoma.


**Institution Vote**

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
<th>ABSENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>20</td>
<td>0</td>
<td>0</td>
<td>7</td>
</tr>
</tbody>
</table>
### External request:

Submission from Exelixis company (4/12/19) to Consider the inclusion of cabozantinib as a second-line systemic therapy option for osteosarcoma relapsed/refractory or metastatic disease and Ewing sarcoma relapsed/refractory or metastatic disease.

**Change not made**

Based on a review of data and discussion, the panel consensus did not support the inclusion of cabozantinib as a second-line systemic therapy option for relapsed/refractory or metastatic osteosarcoma and Ewing sarcoma due to insufficient available data.

See Submission for references.

### Internal request:

Comment to consider the inclusion of everolimus ± to sorafenib for second-line relapsed/refractory or metastatic disease for osteosarcoma.

**Addition at call/meeting**

Based on the data in the noted reference and discussion, the panel consensus was to include everolimus ± sorafenib for second-line relapsed/refractory or metastatic disease for osteosarcoma. This is a category 2B recommendation.


### Internal request:

Comment to consider the inclusion of regorafenib for second-line relapsed/refractory or metastatic disease for osteosarcoma.

**Addition at call/meeting**

Based on the data in the noted reference and discussion, the panel consensus was to include regorafenib for second-line relapsed/refractory or metastatic disease for osteosarcoma. This is a category 1 recommendation.

<table>
<thead>
<tr>
<th>BONE-B (3 of 5)</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Internal request:</td>
<td>Consider removal of the regimen ifosfamide, cisplatin and epirubicin for first-line primary/neoadjuvant/adjuvant therapy or metastatic osteosarcoma.</td>
<td>Removal at call/meeting</td>
<td>The panel consensus was to remove the regimen ifosfamide, cisplatin and epirubicin for first-line primary/neoadjuvant/adjuvant therapy or metastatic disease for osteosarcoma due to limited clinical use.</td>
<td>20</td>
</tr>
<tr>
<td>BONE-B (3 of 5)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Internal request:</td>
<td>Consider removal of Radium 233 (Ra 233) for second-line relapsed/refractory or metastatic disease for osteosarcoma.</td>
<td>Removal at call/meeting</td>
<td>The panel consensus was to remove Radium 233 for second-line relapsed/refractory or metastatic disease for osteosarcoma due to limited clinical use.</td>
<td>20</td>
</tr>
</tbody>
</table>